Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study

被引：0
作者：
Ambrose, Chris [1 ]
Colice, Gene [1 ]
Salapa, Kinga [2 ]
Parnes, Jane [3 ]
Corren, Jonathan [4 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] AstraZeneca, Warsaw, Poland
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
075
引用
收藏
页码：AB25 / AB25
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
    Menzies-Gow, Andrew
    Corren, Jonathan
    Bourdin, Arnaud
    Chupp, Geoffrey
    Israel, Elliot
    Griffiths, Janet
    Hellqvist, Asa
    Bowen, Karin
    Kaur, Primal
    Almqvist, Gun
    Ponnarambil, Sandhia
    Colice, Gene
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB249 - AB249
  • [32] EFFECT OF TEZEPELUMAB ON PATIENT-REPORTED ACTIVITY LEVELS AND SLEEP DISTURBANCE IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM THE PHASE 3 NAVIGATOR STUDY
    Lugogo, Njira L.
    Kraft, Monica
    Corren, Jonathan
    Bober, Magdalena
    Shenoy, Kartik V.
    Shenoy, Sonia
    Chandarana, Shradha
    Ambrose, Christopher S.
    CHEST, 2024, 166 (04) : 4651A - 4653A
  • [33] TEZEPELUMAB REDUCES MUCUS PLUGGING IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA: THE PHASE 2 CASCADE STUDY
    Nordenrnark, L.
    Emson, C.
    Hellqvist, A.
    Johnston, J.
    Greberg, H.
    Griffiths, J. M.
    Newell, J. D.
    Pames, J. R.
    Colice, G.
    Brightling, C. E.
    THORAX, 2022, 77 : A32 - A32
  • [34] Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study
    Corren, J.
    Bourdin, A.
    Chupp, G.
    Israel, E.
    Ambrose, C. S.
    Ackert, J. Llanos
    Kmita, K.
    Cook, B.
    Colice, G.
    Menzies-Gow, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [35] Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies
    Ian D. Pavord
    Christopher E. Brightling
    Stephanie Korn
    Nicole L. Martin
    Sandhia S. Ponnarambil
    Nestor A. Molfino
    Jane R. Parnes
    Christopher S. Ambrose
    Pulmonary Therapy, 2025, 11 (2) : 315 - 325
  • [36] Effect Of Tezepelumab On Rescue Medication Use And Night-Time Awakenings In Patients With Severe, Uncontrolled Asthma: Results From The NAVIGATOR Study
    Carr, Warner
    Ambrose, Chris
    Hunter, Gillian
    Ponnarambil, Sandhia
    Llanos-Ackert, Jean-Pierre
    Clarke, Nicole
    Cook, Bill
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB14 - AB14
  • [37] Tezepelumab Efficacy in Patients with Allergic and Non-Allergic Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
    Corren, Jonathan
    Colice, Gene
    Salapa, Kinga
    Bowen, Karin
    Llanos-Ackert, Jean-Pierre
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB157 - AB157
  • [38] Tezepelumab Reduces Patient-reported Cough and Phlegm Production in Patients With Severe, Uncontrolled Asthma: Results From the Phase 3 NAVIGATOR Study
    Castro, M.
    Kraft, M.
    Ambrose, C. S.
    Martin, N.
    Clarke, N.
    Spahn, J. D.
    Llanos, J.
    Ponnarambil, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [39] Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma With Aspirin-exacerbated Respiratory Disease: Results From the NAVIGATOR Study
    Bernstein, Jonathan
    Laidlaw, Tanya
    Buccheit, Kathleen
    Cahill, Katherine
    Martin, Nicole
    Ponnarambil, Sandhia
    Parikh, Bhavini
    Ambrose, Christopher
    Lindsley, Andrew
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB101 - AB101
  • [40] Efficacy Of Tezepelumab In Patients With Severe, Uncontrolled Asthma Grouped By Median Baseline Serum IL-5 And IL-13 Levels: Results From The Phase 3 NAVIGATOR Study
    Hoyte, Flavia
    Mathur, Sameer
    Carr, Tara
    Martin, Nicole
    Ponnarambil, Sandhia
    Llanos, Jean-Pierre
    Spahn, Joseph
    Reeh, Kaitlin
    Ambrose, Chris
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB305 - AB305
12345